

## Strides Pharma buys & in-licenses generic brands from Sandoz for \$12 M

17 March 2026 | News

**To position Strides as one of the top five pharmaceutical players in the Sub-Saharan Africa region**



Strides Pharma Science has announced that its step-down subsidiary, Strides Pharma International AG (SPIAG), has entered into definitive agreements with Sandoz AG, Switzerland and its group entities for the acquisition and in-licensing of a portfolio of branded generic products across Sub-Saharan Africa (SSA).

The agreement spans four key markets—Western Sahara (covering 10 countries), Ghana, Nigeria, and Kenya. The branded generics portfolio of Sandoz, as a part of this deal, includes multiple brands across anti-infective, cardiovascular, and dermatology therapeutic segments. Several of these products individually deliver annual sales exceeding \$1 million, reflecting their established brand equity and market demand.

The transaction includes a portfolio comprising products that are being fully acquired by Strides, as well as select products that Strides will continue to market on behalf of Sandoz. To ensure the uninterrupted availability of these critical brands, Strides will also enter into a Manufacturing and Supply Agreement with Sandoz for their continued production and supply.

With the combined strength of Strides' existing business and the branded portfolio being acquired from Sandoz, Strides is expected to become one of the top five pharmaceutical companies in the SSA region by sales and among the top two players in the representable market.

The acquisition opens new commercial channels through deeper access to prescriber bases, pharmacies, clinics, and

healthcare institutions where Sandoz products already have strong presence. These synergies, combined with operational efficiencies from a strengthened commercial and supply chain platform, are expected to drive superior market coverage and long-term value creation.

The initial consideration for the transaction is \$12 million, payable at closing and is expected to be funded through internal accruals. The transaction is expected to be EPS accretive, supported by profitable branded sales, synergy realisation, and improved operating leverage.

The transaction is expected to close by the end of Q2 FY27 (Quarter Ending 30<sup>th</sup> September 2026), subject to customary closing conditions, including regulatory and antitrust approvals in applicable jurisdictions.